Argenx Se · EURONEXT:ARGX
Argenx — Q1 2020 Earnings Presentation
15 slides from Argenx's earnings presentation, May 14, 2020
Slide 1: 1Q20 Financial Results & Business Update
1Q20 Financial Results & Business Update 14 May 2020
Slide 2: Forward-Looking Statements
Forward-Looking Statements ! This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter
Slide 3: Navigating The Impact Of COVID-19
Navigating The Impact Of COVID-19 Our Ensuring alignment across our team People Supporting each other in new environment Our Adapting for our patients Implementing opportunities for home infusions Patients and telehealth visits Focused on continuity Our ADAPT readout on track for mid-2020 and BLA Bu
Slide 4: Agenda for today
Agenda for today 1 COVID-19 impact 2 ARGX-117 development 3 Efgartigimod Ph2 clinical trial in pemphigus 4 Commercial launch preparations 5 Financial results 6 Q&A 4
Slide 5: Innovative ADAPT Trial Designed To Meet Clinical Practice
Innovative ADAPT Trial Designed To Meet Clinical Practice Patient population Open-label Extension Primary endpoint readout at week 8 consistent with Retreat as needed to simulate clinical Duration of benefit measured over 26 weeks Phase 2 practice Up to 2 First treatment cycle retreatment cycles 10m
Slide 6: Deep Antibody Pipeline Of Differentiated Candidates
Deep Antibody Pipeline Of Differentiated Candidates Program Target Indication Preclinical Phase 1 Phase 2 Phase 3 Partner IV MG SC Bridging MG Efgartigimod IV ITP Initiated 4Q19 IV + SC ITP m FcRn IV ITP IV PV SC CIDP Initiated 4Q19 TBD 5th Indication Newly diag. AML (unfit) Cusatuzumab + AZA CULMIN
Slide 7: Clinical Trials Of Our Partners
Clinical Trials Of Our Partners Cusatuzumab Janssen Ongoing clinical trials paused including CULMINATE and cusa/aza/ven triple combo ARGX-112/LP0145 LEO Pharma Ongoing Phase 1 clinical trial paused AbbVie ARGX-115/ABBV-151 Ongoing Phase 1 clinical trial remains open 7
Slide 8: Evaluate C2 Inhibitor ARGX-117 In COVID-19 Patients
Evaluate C2 Inhibitor ARGX-117 In COVID-19 Patients • Complement system Classical Lectin Alternative IgG IgM Mannose sugar Foreign surface • Activates inflammation response C1 • Leads to ARDS (Acute Respiratory qrs MBL C3 Distress Syndrome) in coronavirus infections MASPs C4 CFB CFD C2 • C2 • Sits a
Slide 9: Adaptive Phase 2 Proof-Of-Concept Trial
Adaptive Phase 2 Proof-Of-Concept Trial Cohort 1 Cohort 2 Cohort 3 Cohort 4 6 5 8 15 Efgartigimod dose (mg/kg) 10 25 Induction 4 Weekly infusions Weekly infusions until EoC Maintenance period (weeks) 6 8 12 Up to 34 Maintenance Dosing 2 doses at weeks 2 and 6 Every other week Discretion of investiga
Slide 10: Phase 2 Proof-Of-Concept Data Support Advancement To Phase 3
Phase 2 Proof-Of-Concept Data Support Advancement To Phase 3 Fast onset of action 90% disease control (28/31 patients) – majority after 1-2 infusions Median time to DC: 15 to 22 days (mono/combo therapy) Deep responses 70% complete clinical remission (7/10 patients) on optimized dosing* Time to CR:
Slide 11: Potential To Disrupt Current MG Treatment Paradigm
Potential To Disrupt Current MG Treatment Paradigm Vision: Efgartigimod positioned to be used early and more broadly within existing paradigm efgartigimod Delay or Steroids IVIg Eliminate ISTs ACIs Taper Ritux Soliris Current MG Treatment Paradigm ACIs (mestinon) Steroids most common ISTs used for s
Slide 12: Addressable MG Market: Patients Who Need Therapy Beyond Steroids
Addressable MG Market: Patients Who Need Therapy Beyond Steroids 65,000 adult myasthenia gravis patients in 85% U.S. of MG patients have generalized form of disease 55,000 patients have generalized form of myasthenia gravis 36% 20,000 patients require of patients require treatment more aggressive be
Slide 13: 1Q2020 Financials
1Q2020 Financials Three months ended March 31 in thousands of € 2020 2019 Variance Revenue 19,171 36,453 (17,282) Other operating income 4,237 3,564 673 Total operating income 23,408 40,017 (16,609) Research and development expenses (94,917) (34,752) (60,165) Selling, general and administrative expe
Slide 14: Our Key Priorities In 2020
Our Key Priorities In 2020 1 Prepare for launch Execute pipeline: 2 5 registrational and 7 Phase 1-2 trials 3 Expand through Immunology Innovation Program 14
Slide 15: Q&A
4 argenx « visit argenx.com